Mitoxantrone
- Generic Name
- Mitoxantrone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
- Conditions
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02553460
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Rady Children's Hospital and Health Center, San Diego, California, United States
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Children's Mercy Hospital Kansas City
- Target Recruit Count
- 2
- Registration Number
- NCT02535806
- Locations
- 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: DasatinibDrug: prednisoneDrug: cyclophosphamideDrug: daunorubicinDrug: vincristineDrug: cytarabineDrug: mercaptopurineDrug: methotrexateDrug: dexamethasoneDrug: mitoxantroneDrug: etoposideProcedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2022-08-03
- Target Recruit Count
- 30
- Registration Number
- NCT02523976
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Alvocidib Biomarker-driven Phase 2 AML Study
- Conditions
- Interventions
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT02520011
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Morristown Cancer Center, Morristown, New Jersey, United States
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT02518750
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02419755
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02400281
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
- Conditions
- Interventions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 91
- Registration Number
- NCT02306291
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT02303821
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸West Virginia University Medicine Childrens, Morgantown, West Virginia, United States
🇹🇷Medical Park Bahcelievler Hastanesi, Istanbul, Turkey
A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- South China Children's Leukemia Group
- Target Recruit Count
- 176
- Registration Number
- NCT02200978
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.